8-K: Liminatus Pharma Receives Nasdaq Non-Compliance Notice

Liminatus Pharma, Inc. announced it received a Nasdaq non-compliance notice due to a delay in filing its quarterly report, risking its stock listing.

Summary

• Liminatus Pharma, Inc. received a notice from Nasdaq on August 22, 2025, indicating non-compliance with Listing Rule 5250(c)(1).
• The non-compliance is due to the delay in filing its Quarterly Report on Form 10-Q for the period ended June 30, 2025.
• The deficiency letter does not immediately affect the listing of the company's common stock, which continues to trade under the symbol LIMN.
• The company has 60 calendar days, until October 21, 2025, to submit a plan to regain compliance.
• If the plan is accepted, Nasdaq may grant an exception of up to 180 calendar days from the filing's due date, or until February 16, 2026, to regain compliance.
• If the compliance plan is not accepted, the company can appeal the decision to a Nasdaq Hearings Panel.
• Liminatus Pharma is actively working to complete and file the Form 10-Q as soon as practicable.
• A press release announcing the non-compliance notice was issued on August 25, 2025, as required by Nasdaq rules.

Sentiment

Score: 3

Explanation: The filing indicates a significant regulatory compliance issue (Nasdaq non-compliance due to delayed 10-Q), which is a negative development. While there's no immediate delisting, the risk is substantial, and it raises concerns about operational execution and financial reporting integrity. The company is pre-clinical, making such issues more impactful.

Positives

• The deficiency notice has no immediate effect on the listing of the company's common stock, which continues to trade on Nasdaq.
• The company has a defined process and timeline to regain compliance, including the opportunity to submit a plan and appeal.

Negatives

• Received a notice of non-compliance from Nasdaq for failing to file its Quarterly Report on Form 10-Q for the period ended June 30, 2025, by the due date.
• Failure to regain compliance could lead to the delisting of the company's common stock from Nasdaq.
• The company is a pre-clinical stage biopharmaceutical company, which often implies higher reliance on capital markets and investor confidence, making compliance issues more impactful.

Risks

• Delisting Risk: There is no assurance that Nasdaq will accept the company's plan to regain compliance or that the company will regain compliance within the specified period, potentially leading to delisting.
• Operational Disruption: The delay in filing the 10-Q suggests potential internal operational or financial reporting challenges.
• Investor Confidence: Non-compliance issues can erode investor confidence and negatively impact stock price.
• Future Capital Raising: Delisting or prolonged non-compliance could hinder future capital raising efforts, critical for a pre-clinical stage biopharmaceutical company.

Future Outlook

The company intends to file its Form 10-Q as soon as practicable and submit a plan to regain compliance with Nasdaq rules. However, there is no assurance that Nasdaq will accept the plan or that the company will successfully regain compliance within the given timeframe or in the future.

Management Comments

• The Company is in the process of completing the Form 10-Q and intends to file it as soon as practicable.

Industry Context

As a pre-clinical stage biopharmaceutical company, Liminatus Pharma is highly dependent on investor confidence and access to capital markets to fund its research and development, particularly for its immune-modulating cancer therapies like IBA101. Regulatory compliance, especially maintaining a Nasdaq listing, is crucial for such companies to attract and retain investors. A non-compliance notice, even without immediate delisting, can signal operational issues and raise concerns about the company's ability to progress its drug candidates.

Comparison to Industry Standards

• This situation represents a failure to meet a fundamental regulatory reporting standard common across all publicly traded companies.
• While specific financial performance comparisons are not applicable here, the delay in filing a Form 10-Q is a serious compliance lapse.
• Companies like Moderna (MRNA) or BioNTech (BNTX), while much larger and further along, consistently meet their reporting obligations, setting a benchmark for operational rigor.
• Smaller, pre-clinical biotechs often face greater scrutiny regarding their financial stability and operational execution, making such a compliance issue particularly concerning compared to more established industry players.

Stakeholder Impact

• Shareholders: Face increased risk of stock delisting, potential erosion of share value, and reduced liquidity if delisted. Uncertainty regarding the company's financial health due to delayed reporting.
• Investors: May view the company as higher risk, potentially impacting future investment decisions and access to capital.
• Employees: Potential for increased uncertainty regarding the company's future stability and operational continuity.
• Regulatory Authorities: Nasdaq has issued a formal notice, and continued non-compliance could lead to further regulatory action.

Next Steps

• Complete and file the Quarterly Report on Form 10-Q for the period ended June 30, 2025, as soon as practicable.
• Submit a plan to Nasdaq to regain compliance by October 21, 2025.
• If the plan is accepted, work to regain full compliance by February 16, 2026.
• Prepare for a potential appeal to a Nasdaq Hearings Panel if the compliance plan is not accepted.

Key Dates

Recommendation

The receipt of a Nasdaq non-compliance notice due to a delayed financial filing is a serious red flag for investors. While there's a grace period, the underlying issue of delayed reporting suggests potential operational or financial reporting weaknesses. For a pre-clinical biopharmaceutical company, maintaining market access and investor confidence is paramount. This event introduces significant regulatory risk, potential for delisting, and could severely impact the company's ability to raise future capital, which is critical for its long-term viability. Investors should consider selling to mitigate exposure to these heightened risks.

Keywords

Liminatus Pharma, LIMN, Nasdaq, delisting, non-compliance, Form 10-Q, quarterly report, biopharmaceutical, cancer therapies, IBA101, CD47 antibody, SEC filing, regulatory notice